CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study-Reference-Cited by-同舟云学术

CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study

Published:2021-01 Issue:1 Volume:22 Page:118-131
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

O'Hara Mark H,O'Reilly Eileen M,Varadhachary Gauri,Wolff Robert A,Wainberg Zev A,Ko Andrew H,Fisher George,Rahma Osama,Lyman Jaclyn P,Cabanski Christopher R,Mick Rosemarie,Gherardini Pier Federico,Kitch Lacey J,Xu Jingying,Samuel Theresa,Karakunnel Joyson,Fairchild Justin,Bucktrout Samantha,LaVallee Theresa M,Selinsky Cheryl,Till Jacob E,Carpenter Erica L,Alanio Cécile,Byrne Katelyn T,Chen Richard O,Trifan Ovid C,Dugan Ute,Horak Christine,Hubbard-Lucey Vanessa M,Wherry E John,Ibrahim Ramy,Vonderheide Robert H

Funder

Bristol-Myers Squibb

Cancer Research Institute

Parker Institute for Cancer Immunotherapy

Publisher

Elsevier BV

Subject

Oncology

Reference16 articles.

1. Cancer statistics, 2020;Siegel;CA Cancer J Clin,2020

2. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial;Von Hoff;J Clin Oncol,2011

3. Phase IB/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313;Ramanathan;J Clin Oncol,2019